An incomplete spinal cord injury (SCI) results in profound impairments in volitional strength and reflex excitability, which contribute to loss of function. Human and animal models suggest that disruption of monoaminergic input, particularly serotonin (5HT), from supraspinal centers contributes this impaired motor function following SCI. In the present study, we investigated the effects of 5HT medications on motor function in individuals with chronic (> 1 yr) SCI. Clinical measures of strength, spasticity/spasms, and walking ability were assessed on 12 individuals with chronic incomplete SCI following acute administration of either 8 mg cyproheptadine, a 5HT antagonist, or 10 mg escitalopram, a selective 5HT reuptake inhibitor (SSRI), in a double-blinded, randomized, crossover fashion. Results indicate that 5HT medications modulate both volitional and reflexive behaviors with little change in walking performance; 5HT antagonist medications depressed clinical measures of strength and spasticity/spasms whereas SSRIs augmented both strength and spasticity/spasms. These changes are consistent with the dysregulation of 5HT-sensitive spinal neurons following SCI. This understanding may augment clinicians' awareness of the motor consequences of 5HT medications.
Introduction
Incomplete spinal cord injury (SCI) can result in profound impairments in motor control and limitations in function. Two prominent, functionally relevant impairments include weakness, defined as deficits in force generation during maximal voluntary effort contractions, and hyperactive reflexes which encompasses spasticity, defined as velocity dependent increases in stretch reflex excitability, and spasms, defined here as sustained, involuntary muscle activation. A variety of pharmacological, physical and/or surgical interventions have been directed towards improving function thorough amelioration of these impairments, although their relative efficacy is unclear.
The mechanisms underlying spasticity and spasms following SCI are multifaceted and include changes in both afferent pathways and spinal circuits. One mechanism underlying spastic motor behaviors that has gained considerable support is the role of altered spinal motoneuron excitability following SCI. Under healthy conditions, synaptic depolarization of the motoneuron is influenced by persistent inward (Ca 2+ and Na + ) currents (PICs), which amplify and sustain membrane depolarization. Motoneuron PIC activation, and the resulting motor output, is strongly influenced by spinal concentrations of endogenous neuromodulators, in particular serotonin (5HT). 1 The SCI disease progression results in structural changes to these 5HT receptors in the chronic stages post-injury, allowing for PIC activation with minimal residual descending 5HT. [2] [3] [4] Dysregulation of PIC activation contributes to the presence of both spasticity and spasms; accordingly, medications which block 5HT activity may decrease spasticity/spasms, 3 whereas medications which augment 5HT bioavailability may increase spasticity/spasms. may still modulate motor output. For example, PIC activation may help explain the observations of increased time to task failure during sustained motor activity and increases in peak volitional torque generation during maximal effort contractions in patients with incomplete SCI. [8] [9] [10] Further, medications which decrease 5HT may decrease volitional strength and functional performance following SCI, 11, 3 where as preliminary data suggests medications which augment 5HT may increase strength.
12, 13
The current study assesses acute alterations in clinical measures of volitional strength, spasticity/spasms, and locomotor function following single dose administration of 5HT medications in subjects with incomplete SCI. The primary hypotheses were that administration of a 5HT
antagonist (cyproheptadine) would depress volitional and reflexive motor function, whereas an agent that augmented 5HT bioavailability, such as a selective 5HT reuptake inhibitor (SSRI; escitalopram), would increase volitional and reflex function. Understanding how these medications affect motor output following SCI may have an important role in clinical decision making, particularly as a large number of individuals with SCI utilize medications which modulate synaptic 5HT activity.
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Materials and Methods
Twelve individuals with chronic motor incomplete SCI participated in a double-blinded, randomized crossover design study to assess the acute effects of over-encapsulated, oral administration of a 5HT
antagonist (8mg cyproheptadine, Periactin, Merck Inc.) and a SSRI (10 mg escitalopram oxalate, Lexapro, Forest Pharmaceuticals Inc.) on clinical assessments of motor activity. The dosage of medications was chosen upon previous published and unpublished data. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
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Lower extremity reflex behaviors were assessed using both the modified Ashworth assessment (mAsh) and the Spinal Cord Assessment Tools for Spastic Reflexes (SCATS). The mAsh assesses resistance to rapid joint movement applied by the experimenter to the passive subject. This evaluation is used to assess spasticity of bilateral knee extensors and flexors using a 0-5 scale ranging from 'no increase in muscle tone' to 'complete rigidity.' Scores were summed bilaterally for a total possible score of 20, with individual assessments also analyzed separately. The SCATS is a clinical evaluation of 3 types of lower extremity spasms (flexor spasms, extensor spasms, plantarflexor clonus). Each spasm is graded on a 0-3 scale based upon the amplitude or duration of reflex activity.
Data were summed bilaterally for a total score of 18, with individual assessments also analyzed separately.
Walking function was assessed using an instrumented walking platform (GaitMatII ®, Equitest, Chalfont, PA). Walking data was collected during walking over 2-3 trials at the patients fastest-possible velocity with assistive devices and lower extremity bracing below the knee as needed.
Primary outcomes included velocity, step length, and cadence.
Potential differences in clinical measures from baseline values for either medication were assessed using a Wilcoxon Signed Rank; when non-significant changes were observed, baseline measures were averaged. Reliability between baseline testing was assessed using a ICC(2,1) model and the variability was described using the median of the absolute difference between testing sessions. A Friedman's test was used to assess changes between baseline, 5HT antagonist and SSRI conditions. A post-hoc Wilcoxon Signed Rank was used to determine specific differences. Within subject change scores for each medication were calculated and analyzed in a similar manner.
Potential correlations among variables were assessed using Spearman Rank. (Fig 1D-F) . Change scores in individual mAsh assessments demonstrate significant differences between medications for both knee flexor and knee extensor spasticity (both p<0.05). Change scores for individual SCATS assessments demonstrate significance for extensor spasms and plantarflexor clonus (both p<0.05), flexor spasms approached significance (p=0.06).
Modulation of volitional and reflexive motor output
Changes in strength and spastic motor behaviors described above appeared to co-vary with the different 5HT medications. Significant correlations between both LEMS and mAsh change scores (rho=0.53, p=0.01, Fig 2A) , and LEMS and SCATS change scores were observed (rho=0.54, p<0.01, Fig 2B) . This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
Modulation of walking performance
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Discussion
In the present investigation, single-dose administration of medications which modulate 5HT bioavailability demonstrated divergent trends in motor function in subjects with motor incomplete SCI. Namely 5HT-antagonists decreased clinical measures of both strength and spasticity/spasms, while administration of SSRIs augmented both behaviors. Acute administration of either medication appears to be ineffective at improving locomotor function.
Serotonergic modulation of motor output
The finding that volitional strength and spastic motor behaviors co-vary following different 
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Changes in strength and reflex activity were relatively consistent following either medication, with few outliers from different subjects on separate testing days, (see Figure 2 ). However, a rather large increase in SCATS values was observed following SSRI medication ( Figure 1F ). This behavior may be related to the time-dependent assessment of extensor and clonic spasms in the SCATS and suggests that increased persistence of spasms with SSRIs may account for the large differences. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
Despite this observation, the general correlations between medication-induced changes in strength and spasticity/spasms were observed.
Walking performance decreased following administration of either 5HT medications, although only significantly following 5HT-antagonists. These findings contrast with previous investigations that demonstrate improved walking ability following longer-duration cyproheptidine administration in patients with incomplete SCI. 14, 15 This decline may have been due to recruitment of relatively higher functioning patients in the present study, where one subject presented with a LEMS of 50. However, all patients demonstrated substantial gait impairments at baseline, with little potential for ceiling effects. Mechanisms underlying this immediate decline in speed following either medication are unclear, as both strength and reflex activity contribute to locomotor function. A likely contributing factor was use of altered neuromuscular control strategies following either medication, with limited time allowed for subjects to adapt to the agents. As such, subjects may have chosen to walk at slower, more stable speeds. Long term application of these medications may allow adaptation to the changes in neuromuscular excitability.
Clinical implications
Despite significant, immediate changes in motor impairments following either 5HT agent, an important clinical implication is the lack of substantial positive improvements in functional walking performance. While the use of SSRIs to improve motor function following neurological injury has been suggested, 16 animal and human studies suggest combined pharmacological and physical (training) interventions to maximize therapeutic benefits. 17, 18 However more data is required as recent studies also suggest that use of SSRIs may contribute to poorer rehabilitation outcomes. 19 While the motor consequences of these agents are of primary interest, the use of SSRIs in SCI is common, 20, 21 and the resultant side-effects may not be well-understood. As such, patients may be prescribed anti-spastic agents to counteract the observed increase in spasticity with SSRIs. Use of This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
